Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Malignancy and hypercoagulability: a two-way association revisited

Abstract

Increasing evidence is highlighting the relationship between malignancy and hypercoagulability as a bidirectional association. We herein share our experience with a patient in whom such an association may be entertained. The patient, who had a history of venous thromboembolism, presented to our care with manifestation of stroke. Extensive workup revealed that the patient carries prothrombotic mutations in the prothrombin and methylenetetrahydrofolate reductase genes. The patient, a non-smoker, was also diagnosed with non-small cell lung carcinoma. The possible association between the patient’s malignancy and prothrombotic state are further discussed.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Agnelli G, Verso M (2005) Thrombosis and cancer: clinical relevance of a dangerous liaison. Haematologica 90:155–156

  2. 2.

    Franchini M, Veneri D, Salvagno GL et al (2006) Inherited thrombophilia. Crit Rev Clin Lab Sci 43:249–290

  3. 3.

    Hankey GJ, Eikelboom JW, van Bockxmeer FM et al (2001) Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 32:1793–1799

  4. 4.

    Graus F, Rogers LR, Posner JB (1985) Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64:16–35

  5. 5.

    Taccone FS, Jeangette SM, Blecic SA (2008) First-ever stroke as initial presentation of systemic cancer. J Stroke Cerebrovasc Dis 17:169–174

  6. 6.

    Decousus H, Moulin N, Quenet S et al (2007) Thrombophilia and risk of venous thrombosis in patients with cancer. Thrombosis Res 120(Suppl 2):S51–S61

  7. 7.

    Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124(Suppl 3):S58–S68

  8. 8.

    Vairaktaris E, Yapijakis C, Wiltfang J et al (2005) Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 25:2561–2565

  9. 9.

    Batistelli S, Stefanoni M, Genovese A et al (2006) Prevalence of factor V leiden and prothrombin G20210A in patients with gastric cancer. World J Gastrornterol 12:4179–4180

  10. 10.

    Smorenburg SM, Van Noorden CJF (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93–105

  11. 11.

    Kuderer NM, Khorana AA, Lyman GH, Francis CW (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110:1149–1160

Download references

Author information

Correspondence to Ali T. Taher.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aoun, E.G., Musallam, K.M., Abou-Ghazal, M. et al. Malignancy and hypercoagulability: a two-way association revisited. J Thromb Thrombolysis 30, 340–341 (2010). https://doi.org/10.1007/s11239-010-0458-4

Download citation

Keywords

  • Hypercoagulability
  • Lung cancer
  • Malignancy
  • Stroke
  • Thrombophilia
  • Venous thromboembolism